pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Approval · news · pharmadog
← back to Approval
News · Approval
1,551
stories
23d
Lilly shuffles business structure; Novartis writes off part of Avidity deal
biopharma dive
23d
Lilly’s retatrutide trounces Novo’s Ozempic in diabetes, weight loss
biospace
24d
STAT+: Lilly says ‘triple-G’ drug beat Novo’s Ozempic in diabetes study
stat
24d
Data leak kickstarts ESMO, BMS reports autoimmune CAR T death, pharma M&A outpaces 2025
biospace
24d
STAT+: As Epic’s dominance grows, its iron grip is choking innovation in health technology
stat
24d
Lilly’s retatrutide bests Ozempic on blood sugar, weight loss in phase 3 diabetes showdown
fiercebiotech
24d
5 new drug launches that defied industry expectations
biospace
24d
Biotechs going to market alone must learn to go global
biospace
24d
STAT+: After two deaths in autoimmune cell therapy trial, Artiva is shutting down
stat
24d
STAT+: FDA offers new details on quicker approval pathway for personalized gene therapies
stat
24d
STAT+: Pharmalittle: We’re reading about a Novo setback in court, a House probe into big PBMs, and more
stat
24d
Novartis faces $1.9B hit from Avidity fail but maintains confidence in $12B buy
biospace
25d
A possible treatment for brain-eating amoebas, found in the sea
stat
25d
Parkinson’s-focused Aspen and bispecific biotech Bambusa both shoot for $134M IPOs
fiercebiotech
25d
GSK’s B7-H3 ADC drives 67% cancer risk reduction in Hansoh's phase 3 China trial
fiercebiotech
25d
STAT+: GSK sees its return to cancer start to pay off
stat
25d
Roche’s changing plans show how MFN is complicating European drug launches
endpoints
25d
BioNTech, DualityBio say ADC had ‘modest’ benefit in breast cancer study
biopharma dive
25d
ESMO ‘26: A cancer vaccine debate, Roche’s KRAS progress and Amgen’s ‘unprecedented’ data
biopharma dive
25d
STAT+: Merck ADC drug cut risk of death by one-third in advanced endometrial cancer
stat
25d
ESMO 2026: Amgen’s Imdelltra slashes death risk by nearly 60% in small cell lung cancer
biospace
25d
STAT+: Incyte pancreatic cancer medicine induces lasting tumor responses, company says at ESMO
stat
25d
STAT+: Five biotech updates to read after ESMO this weekend
stat
25d
Corxel to take oral GLP-1 public in the US via SPAC
endpoints
26d
Genmab’s ADC beats survival expectations in Phase 3 ovarian cancer trial
biospace
26d
BioNTech sees ‘limited’ benefit to ADC after phase 3 reveals modest efficacy, ILD cases
fiercebiotech
26d
STAT+: Moderna CEO on what’s next after success in cancer vaccine
stat
26d
ESMO: Tango trims headcount after impressing analysts with ‘highly synergistic’ RevMed combo
fiercebiotech
26d
Neurogene, Taysha near finish line in ‘two-horse race’ for first Rett syndrome gene therapy
biospace
26d
Australia's clinical trial advantage gains ground amid U.S. uncertainty
biospace
← prev
page 9 of 52
next →